Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the First Quarter 2026 Agios Financial Results and Business Highlights.
Agios Pharmaceuticals Inc. (AGIO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 5,684,000 | $192,289,720 | +11% | 1.1% |
| 2. | 3,200,000 | $108,256,000 | +7% | 1.92% | |
| 3. | Armistice Capital Steven Boyd | 2,716,000 | $91,882,280 | -11% | 1.63% |
| 4. | D E Shaw D. E. Shaw | 2,681,169 | $90,703,947 | +46% | 0.05% |
| 5. | Lynx1 Capital Management Weston Nichols | 2,611,568 | $88,349,345 | +3180% | 13.96% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.00 | 40,322 | $1,249,982.00 | 41,722 | 2019-11-13 | Filing | |
| $31.00 | 8,064 | $249,984.00 | 97,567 | 2019-11-13 | Filing | |
| $31.00 | 403,225 | $12,499,975.00 | 1,777,824 | 2019-11-12 | Filing | |
| $83.44 | 200 | $16,688.00 | 571 | 2018-03-16 | Filing | |
| $67.00 | 851,154 | $57,027,318.00 | 1,374,599 | 2018-01-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $34.71 | 3,280 | $113,848.80 | 49,306 | 2026-04-02 | Filing | |
| $34.71 | 2,940 | $102,047.40 | 80,277 | 2026-04-02 | Filing | |
| $34.71 | 3,141 | $109,024.11 | 54,998 | 2026-04-02 | Filing | |
| $34.71 | 3,262 | $113,224.02 | 46,829 | 2026-04-02 | Filing | |
| $34.71 | 2,959 | $102,706.89 | 10,282 | 2026-04-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,754,957 | $194,690,195 | 0% | |
| 2. | 3,364,879 | $113,719,376 | 0% | |
| 3. | 2,632,316 | $89,051,250 | 0% | |
| 4. | 2,611,035 | $88,331,314 | 0% | |
| 5. | 2,704,900 | $80,092,089 | 0.74% |
News See All
10 Oversold Small Cap Stocks to Buy Now
In this article, we will take a look at some of the most oversold small-cap stocks that currently offer attractive upside to investors. On April 18, stocks in the U.S.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2025 Earnings Call Transcript
Operator: Good morning and welcome to Agios Pharmaceuticals, Inc. Fourth Quarter and Full Year 2025 Conference Call. At this time, participants are in a listen-only mode.
Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory
We came across a bullish thesis on Agios Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AGIO.
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK
In a statement, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) said that the FDA officially approved Aqvesme to treat anemia in patients with alpha or beta thalassemia.
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc.
9 Oversold Biotech Stocks to Invest In
Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and healthcare.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Agios Pharmaceuticals Third Quarter 2025 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Agios' request.
Agios Pharmaceuticals, Inc. (AGIO) Advances Pipeline With Tebapivat, AG-236 in Rare Blood Disorders
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a commercial-stage biopharmaceutical company focused on therapies for rare diseases, particularly in cellular metabolism.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.
Hedge Fund Resource Center